Accuray Announces Preliminary First Quarter Fiscal 2022 Financial Results and Raises FY22 Revenue Guidance to range between $420 million to $427 million

Stock Information for Accuray Incorporated

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Accuray Incorporated

Accuray Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024
Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland
Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024
New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System
Accuray Incorporated to Speak at 36th Annual Roth Conference
Accuray Incorporated to Speak at Oppenheimer 34th Annual Healthcare MedTech & Services Conference
Quebec Cancer Center is First in Canada to Treat Cancer Patients Using the Accuray Radixact® System
Accuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.